SARS-CoV-2 vaccination has been launched worldwide to build effective population-level
immunity to curb the spread of this virus. The effectiveness and duration of protective …

Long-term antibody responses and neutralizing activities in response to SARS-CoV-2
infection are not yet clear. Here we quantify immunoglobulin M (IgM) and G (IgG) antibodies …

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
highlights the importance of determining the breadth and durability of humoral immunity to …

In December 2019, an outbreak of a novel coronavirus (SARS-CoV-2) in Wuhan, China
resulted in the current COVID-19 global pandemic. The human immune system has not …

Anti-viral immunity continuously declines over time after SARS-CoV-2 infection. Here, we
characterize the dynamics of anti-viral immunity during long-term follow-up and after …

The immune response to SARS-CoV-2 is critical in controlling disease, but there is concern
that waning immunity may predispose to reinfection. We analyzed the magnitude and …

Highlights•Post-acute sequelae of SARS-CoV-2 (PASC) are associated with persistent
inflammation.•The antigens or other immune stimuli driving PASC are still unclear.•PASC …

With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines,
functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS …

The dynamics, duration, and nature of immunity produced during SARS-CoV-2 infection are
still unclear. Here, we longitudinally measured virus-neutralising antibody, specific …

Understanding the decay and maintenance of long-term SARS-CoV-2 neutralizing
antibodies in infected or vaccinated people and how vaccines protect against other SARS …